{"id":10632,"date":"2025-04-18T16:08:09","date_gmt":"2025-04-18T20:08:09","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=10632"},"modified":"2025-04-18T16:08:09","modified_gmt":"2025-04-18T20:08:09","slug":"sanofi-deepens-autoimmune-push-with-1-8b-ai-biotech-deal","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/sanofi-deepens-autoimmune-push-with-1-8b-ai-biotech-deal\/","title":{"rendered":"Sanofi Deepens Autoimmune Push with $1.8B AI Biotech Deal"},"content":{"rendered":"<p>Sanofi\u2019s ambition to become a dominant force in immunology continues to take shape, as the French pharmaceutical giant signs a deal worth up to $1.8 billion with U.S.-based biotech Earendil Labs. The agreement gives Sanofi exclusive global rights to two bispecific antibody therapies aimed at treating chronic inflammatory diseases.<br \/>\nSanofi, which co-markets the blockbuster anti-inflammatory drug Dupixent with Regeneron, has been undergoing a major pipeline transformation.<br \/>\nThat strategy has been backed by a string of recent high-value deals. In March, Sanofi inked a $1.6 billion agreement with Dren Bio for a CD20-targeting antibody to treat B-cell non-Hodgkin lymphoma. Earlier this month, the company returned to Nurix with a $480 million pact involving a protein degrader targeting autoimmune conditions.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nThe new collaboration with Earendil Labs adds two promising assets to Sanofi\u2019s expanding immunology portfolio. The company will pay $125 million upfront, with an additional $50 million expected in the near term. If both drugs reach the market, Sanofi could pay up to $1.72 billion in development and commercial milestone payments, plus tiered royalties.<br \/>\nThe lead candidate, HXN-1002, targets \u03b14\u03b27 and TL1A to treat ulcerative colitis and Crohn\u2019s disease. HXN-1003, meanwhile, targets TL1A and IL-23, with potential applications in both colitis and skin inflammation.<br \/>\n\u201cWe firmly believe that Sanofi&#8217;s extensive expertise in the autoimmune disease field will significantly accelerate the development of HXN-1002 and HXN-1003, ultimately bringing these potentially life-changing treatments to patients worldwide as soon as possible,\u201d said Zhenping Zhu, M.D., Ph.D., President and co-CEO of Earendil Labs, in a press release.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nEarendil Labs describes itself as a \u201cglobal leader in AI-driven research and development of next-generation biologics therapeutics.\u201d The biotech is affiliated with Helixon Therapeutics, another AI-focused drug discovery firm applying machine learning to protein design.<br \/>\nWith this latest deal, Sanofi continues to position itself at the forefront of immunoscience innovation, betting on emerging technologies like AI to accelerate drug discovery and development in one of the industry\u2019s most competitive therapeutic areas.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi\u2019s ambition to become a dominant force in immunology continues to take shape, as the French pharmaceutical giant signs a deal worth up to $1.8 billion with U.S.-based biotech Earendil Labs. The agreement gives Sanofi exclusive global rights to two bispecific antibody therapies aimed at treating chronic inflammatory diseases. Sanofi, which co-markets the blockbuster anti-inflammatory [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10633,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-10632","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=10632"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10632\/revisions"}],"predecessor-version":[{"id":10634,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10632\/revisions\/10634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/10633"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=10632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=10632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=10632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}